Vaccination against mosquito borne viral infections: Current status

Iranian Journal of Immunology

Volumn 4, Issue 4, 2007, Pages 186-196

  Wiwanitkit, Viroj ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Japanese Encephalitis; Mosquito; Vaccination

Indexed keywords

CHIMERIVAX; DENGUE VACCINE; JAPANESE ENCEPHALITIS VACCINE; JE VACCINE; UNCLASSIFIED DRUG; VACCINE; WEST NILE VACCINE; YELLOW FEVER VACCINE;

ACUTE VISCEROTROPIC DISEASE; AEDES AEGYPTI; ANAPHYLAXIS; ARBOVIRUS; CERTIFICATION; CONFUSION; DENGUE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; EPIDEMIC ENCEPHALITIS; FEVER; HUMAN; MENINGOENCEPHALITIS; METABOLIC DISORDER; MOSQUITO; MYALGIA; NAUSEA; PAPULAR ACRODERMATITIS; PUBLIC HEALTH PROBLEM; RECOMMENDED DRUG DOSE; REVIEW; VACCINATION; VIREMIA; VIRULENCE; VIRUS INFECTION; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS; YELLOW FEVER;

EID: 37249054191     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Fitzgerald MA. Primary, Secondary, and Tertiary Prevention: Important in Certification and Practice. Fitzgerald Health Educa-tion Associate, 2004 Oct, 2007 Nov 25; 1(1). Available at: URL: http://www.fhea.com/CertificationCols/ level_prevention.htm
2. Le Mire J, Arnulf L, Guibert P. Malaria: control strategies, chemoprophylaxis, diagnosis, and treatment. Clin Occup Environ Med. 2004; 4: 143-65.
3. Vasconcelos PF. Yellow Fever. Rev Soc Bras Med Trop. 2003; 36: 275-93.
4. Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001; 1: 11-20.
5. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis. 2004; 27: 319-30.
6. Shoff WH. Yellow fever. E Medicine, eMedicine , [serial online] 2006 Nov [2007 Nov 25]; 1(1). Available at URL: http://www.emedicine.com/ped/topic2463. htm
7. Marianneau P, Despres P, Deubel V. Recent knowledge on the pathogenesis of yellow fever and questions for the future. Bull Soc Pathol Exot. 1999; 92: 432-4.
8. Digoutte JP. Present status of an arbovirus infection: yellow fever, its natural history of hemorrhagic fever, Rift Valley fever. Bull Soc Pathol Exot. 1999; 92: 343-8.
9. Monath TP. Stability of yellow fever vaccine. Dev Biol Stand. 1996; 87: 219-25.
10. Tomori O. Yellow fever in Africa: public health impact and prospects for control in the 21st century. Biomedica. 2002; 22: 178-210.
11. Van Laethem Y. Vaccinations for the traveler. J Pharm Belg. 2002; 57:130-4.
12. Wiwanitkit V. Amazing Thailand year 1998-99 tourist's. Health concepts. Chula Med J. 1998; 42: 975-84.
13. Kirkpatrick BD, Alston WK. Current immunizations for travel. Curr Opin Infect Dis. 2003; 16: 369-74.
14. Potasman I, Pick N, Stringer C, Zuckerman JN. Inadequate protection against yellow fever of children visiting endemic areas. Am J Trop Med Hyg. 2001; 65: 954-7.
15. Cavalcanti DP, Salomão MA, Lopez-Camelo J, Pessoto MA. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health. 2007; 12: 833-7.
16. Kemper CA, Linett A, Kane C, Deresinski SC. Travels with HIV: the compliance and health of HIV-infected adults who travel. Int J STD AIDS. 1997; 8: 44-9.
17. Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis. 2000; 31: 7-8.
18. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ. 2003; 81: 61-70.
19. Tattevin P, Depatureaux AG, Chapplain JM, Dupont M, Souala F, Arvieux C et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS. 2004; 18: 825-7.
20. Leder K, Weller PF, Wilson ME. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis. 2001; 33: 1553-66.
21. Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005; 1: 207-14.
22. Osinusi K , Akinkugbe FM , Akinwolere OA , Fabiyi A . Safety and efficacy of yellow fever vaccine in children less thanone-year-old. West Afr J Med. 1990; 9: 200-3 .
23. Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg. 2007; 101: 967-71.
24. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 2001; 358: 121-2.
25. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001; 358: 98-104.
26. Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell. 2004; 28: 244-8.
27. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vac-cine. 2007; 25: 2758-65.
28. Martins MA, Silva ML, Marciano AP, Peruhype-Magalhães V, Eloi-Santos SM, Ribeiro GL et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin Exp Immunol. 2007; 148: 90-100.
29. Halstead SB, Jacobson J. Japanese encephalitis. Adv Virus Res. 2003; 61: 103-38.
30. Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens. Lancet. 2002; 359: 507-13.
31. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med. 2004; 10: S98-S109.
32. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res. 2002; 33: 330-42.
33. Solomon T. Exotic and emerging viral encephalitides. Curr Opin Neurol. 2003; 16: 411-8.
34. King NJ, Shrestha B, Kesson AM. Immune modulation by flaviviruses. Adv Virus Res. 2003; 60: 121-55.
35. Solomon T. Recent advances in Japanese encephalitis. J Neurovirol. 2003; 9: 274-83.
36. Schwarz TF. Imported vector- and rodent-borne virus infections - an introduction. Arch Virol Suppl. 1996; 11, 3-11.
37. Le DH. Clinical aspects of Japanese B encephalitis in North Vietnam. Clin Neurol Neurosurg. 1986; 88: 189-92.
38. Tiroumourougane SV, Raghava P, Srinivasan S. Japanese viral encephalitis. Postgrad Med. J. 2002; 78: 205-15.
39. Kaur R, Agarwal CS, Das D. An investigation into the JE epidemic of 2000 in Upper Assam - a perspective study. J Commun Dis. 2002; 34:135-45.
40. Kabilan L. Control of Japanese encephalitis in India: a reality. Indian J Pediatr. 2004; 71: 707-12.
41. Sinniah M. A review of Japanese-B virus encephalitis in Malaysia. Southeast Asian J Trop Med Public Health. 1989; 20: 581-5.
42. Public Health - Seattle & King County. Information about Japanese encephalitis vaccine. Healthy People Healthy Community, 2003 Oct, 2007 Nov 25; 1(1). Available at http://www.metrokc.gov/health/prevcont/encephalitis.htm
43. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988; 319: 608-14.
44. Wiwanitkit V. Consideration in immunization in the present day. Taksin Med J. 2001; 22: 250-3.
45. Lo Re V 3rd, Gluckman SJ. Travel immunizations. Am Fam Physician. 2004; 70: 89-99.
46. Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North Am. 2003; 23: 665-97.
47. Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine. 2007; 25: 570-6.
48. Plesner A, Ronne T, Wachmann H. Case-control study of allergic reactions to Japanese encephalitis vaccine. Vaccine. 2000; 18: 1830-6.
49. Sakaguchi M, Nakashima K, Takahashi H, Nakayama T, Fujita H, Inouye S. Anaphylaxis to Japanese encephalitis vaccine. Allergy 2001; 56: 804-5.
50. Sakaguchi M, Inouye S. Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines. Vaccine. 1998; 16: 68-9.
51. Piyasirisilp S, Hemachudha T. Neurological adverse events associated with vaccination. Curr Opin Neurol. 2002; 15: 333-8.
52. Kang NG, Oh CW. Gianotti-Crosti syndrome following Japanese encephalitis vaccination. J Korean Med Sci. 2003; 18: 459-61.
53. Yang Y, Sujan S, Sun F, Zhang Y, Jiang Y, Song J et al. Acute metabolic crisis induced by vaccination in seven Chinese pa-tients. Pediatr Neurol. 2006; 35: 114-8.
54. Schiøler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev. 2007; 3: CD004263.
55. Mairuhu AT, Wagenaar J, Brandjes DP, van Gorp EC. Dengue: an arthropod-borne disease of global importance. Eur J Clin Microbiol Infect Dis. 2004; 23: 425-33.
56. Malavige GN, Fernando S, Fernando DJ, Seneviratne SL. Dengue viral infections. Postgrad Med J. 2004; 80: 588-601.
57. Corwin AL, Larasati RP, Bangs MJ, Wuryadi S, Arjoso S, Sukri N et al. Epidemic dengue transmission in southern Sumatra, Indonesia. Trans R Soc Trop Med Hyg. 2001; 95: 257.
58. Gascon J, Giner V, Vidal J, Jou JM, Mas E, Corachan M. Dengue: a re-emerging disease. A clinical and epidemiological study in 57 Spanish travelers. Med Clin (Barc). 1998; 111: 583-6.
59. Guzman MG, Kouri G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J Clin Virol. 2003; 27: 1-13.
60. Guzman MG, Kouri G. Dengue: an update. Lancet Infect Dis. 2002; 2: 33-42.
61. Wiwanitkit V. Bleeding and other presentations in Thai patients with dengue infection. Clin Appl Thromb Hemost. 2004; 10: 397-8.
62. Shu PY, Huang JH. Current advances in dengue diagnosis. Clin Diagn Lab Immunol. 2004; 11: 642-50.
63. Lopez Antunano FJ, Mota J. Development of immunizing agents against dengue. Rev Panam Salud Publica. 2000; 7: 285-92.
64. Halstead SB, Heinz FX, Barrett AD, Roehrig JT. Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine. 2005; 23: 849-56.
65. Mady BJ, Erbe DV, Kurane I, Fanger MW, Ennis FA. Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. J Immunol. 1991; 147: 3139-44.
66. Yang KD, Yeh WT, Yang MY, Chen RF, Shaio MF. Antibody-dependent enhancement of heterotypic dengue infections in-volved in suppression of IFN gamma production. J Med Virol. 2001; 63: 150-7.
67. Chen RF, Yeh WT, Yang MY, Yang KD. A model of the real-time correlation of viral titers with immune reactions in antibody-dependent enhancement of dengue-2 infections. FEMS Immunol Med Microbiol. 2001; 30: 1-7.
68. Pang T. Vaccines for the prevention of neglected diseases - dengue fever. Curr Opin Biotechnol. 2003; 14: 332-6.
69. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg. 2004; 71: 811-21.
70. Baize S, Marianneau P, Georges-Courbot MC, Deubel V. Recent advances in vaccines against viral haemorrhagic fevers. Curr Opin Infect Dis. 2001; 14: 513-8.
71. Dean CH, Alarcon JB, Waterston AM, Draper K, Early R, Guirakhoo F et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Hum Vaccin. 2005; 1: 106-11.
72. Guharoy R, Gilroy SA, Noviasky JA, Ference J. West Nile virus infection. Am J Health Syst Pharm. 2004; 61: 1235-41.
73. Pauli G. West Nile virus. Prevalence and significance as a zoonotic pathogen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004; 47: 653-60.
74. Zeller HG. West Nile virus infection: a migrating arbovirus of current interest. Med Trop. 1999; 59:490-4.
75. Marfin AA, Gubler DJ. West Nile encephalitis: an emerging disease in the United States. Clin Infect Dis. 2001; 33: 1713-9.
76. MMWR Morb Mortal Wkly Rep. West Nile virus update - United States, January 1-October 16, 2007. Centers for Disease Control and Prevention (CDC). 2007; 56:1084-5. Available at URL: www.cdc.gov/mmwr/preview/mmwrhtml/mm5641a4. htm
77. Thakare JP, Rao TL, Padbidri VS. Prevalence of West Nile virus infection in India. Southeast Asian J Trop Med Public Health. 2002; 33: 801-5.
78. Ceausu E, Erscoiu S, Calistru P, Ispas D, Dorobat O, Homos M et al. Clinical manifestations in the West Nile virus outbreak. Rom. J Virol. 1997; 48: 3-11.
79. Monath TP. Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci. 2001; 951: 1-12.
80. Paramasivan R, Mishra AC, Mourya DT. West Nile virus: the Indian scenario. Indian J Med Res. 2003; 118: 101-8.
81. Monath TP, Arroyo J, Miller C, Guirakhoo F. West Nile virus vaccine. Curr Drug Targets Infect Disord. 2001; 1:37-50.
82. Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ. Equine vaccine for West Nile virus. Dev Biol (Basel). 2003; 114: 221-7.
83. Johnson S. Avian titer development against West nile virus after extralabel use of an equine vaccine. J Zoo Wildl Med. 2005; 36: 257-64.
84. Okeson DM, Llizo SY, Miller CL, Glaser AL. Antibody response of five bird species after vaccination with a killed West Nile virus vaccine. J Zoo Wildl Med. 2007; 38: 240-4.
85. Baitchman EJ, Tlusty MF, Murphy HW. Passive transfer of maternal antibodies to West Nile virus in flamingo chicks (Phoenicopterus chilensis and Phoenicopterus ruber ruber). J Zoo Wildl Med. 2007; 38: 337-40.